Catalyst Pharmaceutical Partners regains compliance for continued listing on The Nasdaq Capital Market

Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that it has received notice from The NASDAQ Stock Market ("NASDAQ") confirming that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

As previously announced, on November 13, 2009 NASDAQ notified the Company that the bid price of its common stock had closed at less than $1.00 per share over the previous 30 consecutive business days, and, as a result, the Company was not in compliance with Listing Rule 5550(a)(2)("Rule"). The Company was provided 180 calendar days, or until May 12, 2010, to regain compliance with the Rule.

On April 26, 2010, NASDAQ notified the Company that the closing bid price of its common stock has been at $1.00 per share or greater for at least 10 consecutive business days. Accordingly, NASDAQ has confirmed to the Company that the Company has regained compliance with the minimum bid price rule and that the matter is now closed.